Addus HomeCare has gotten torched over the last six months - since September 2024, its stock price has dropped 26.9% to $95.71 per share. This may have investors wondering how to approach the situation.
Is now the time to buy Addus HomeCare, or should you be careful about including it in your portfolio? See what our analysts have to say in our full research report, it’s free.
Even though the stock has become cheaper, we're swiping left on Addus HomeCare for now. Here are three reasons why you should be careful with ADUS and a stock we'd rather own.
Why Is Addus HomeCare Not Exciting?
Serving approximately 66,000 clients across 22 states with a focus on "dual eligible" Medicare and Medicaid beneficiaries, Addus HomeCare (NASDAQ:ADUS) provides in-home personal care, hospice, and home health services to elderly, chronically ill, and disabled individuals.
1. Weak Sales Volumes Indicate Waning Demand
Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful Senior Health, Home Health & Hospice company because there’s a ceiling to what customers will pay.
Addus HomeCare’s average billable patients came in at 50,923 in the latest quarter, and over the last two years, averaged 4.8% year-on-year growth. This performance slightly lagged the sector and suggests it might have to lower prices or invest in product improvements to accelerate growth, factors that can hinder near-term profitability.
2. Fewer Distribution Channels Limit its Ceiling
Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.
With just $1.15 billion in revenue over the past 12 months, Addus HomeCare is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive.
3. Free Cash Flow Margin Dropping
Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.
As you can see below, Addus HomeCare’s margin dropped by 3.9 percentage points over the last five years. If its declines continue, it could signal increasing investment needs and capital intensity. Addus HomeCare’s free cash flow margin for the trailing 12 months was 9.6%.
Final Judgment
Addus HomeCare isn’t a terrible business, but it doesn’t pass our bar. After the recent drawdown, the stock trades at 15.9× forward price-to-earnings (or $95.71 per share). Investors with a higher risk tolerance might like the company, but we think the potential downside is too great. We're fairly confident there are better investments elsewhere. Let us point you toward our favorite semiconductor picks and shovels play.
Stocks We Like More Than Addus HomeCare
The Trump trade may have passed, but rates are still dropping and inflation is still cooling. Opportunities are ripe for those ready to act - and we’re here to help you pick them.
Get started by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.
Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free.